CPT-11 for bile-duct and gallbladder carcinoma: A phase II North Central Cancer Treatment Group (NCCTG) study

International Journal of Gastrointestinal Cancer

Volumn 32, Issue 2-3, 2002, Pages 107-114

  Alberts, Steven R ^a   Fishkin, Paul A ^a   Burgart, Lawrence J ^a   Cera, Peter J ^a   Mahoney, Michelle R ^a   Morton, Roscoe F ^b   Johnson, Patricia A ^c   Nair, Suresh ^d   Goldberg, Richard M ^a  

^a MAYO CLINIC   (United States)

^b Iowa Oncology Research Association CCOP   (United States)

^c Carle Cancer Center   (United States)

^d GEISINGER MEDICAL CENTER   (United States)

Author keywords

Bile duct carcinoma; Cholangiocarcinoma; Clinical trial; CPT 11; Gallbladder carcinoma; Irinotecan; Phase II

Indexed keywords

IRINOTECAN;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BILE DUCT CARCINOMA; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FEVER; GALLBLADDER CARCINOMA; HUMAN; INFECTION; LETHARGY; LEUKOPENIA; LIVER TOXICITY; MALE; METASTASIS; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

EID: 0037971057     PISSN: 01694197     EISSN: None     Source Type: Journal    
DOI: 10.1385/ijgc:32:2-3:107     Document Type: Article

References (18)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36.
2. Carriaga MT, Henson DE. Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer 1995;75:171-190.
3. Henson DE, Albores-Saavedra J, Corle D. Carcinoma of the gallbladder, histologic types, stage of disease, grade, and survival rates. Cancer 1992;70:1493-1497.
4. Henson DE, Albores-Saavedra J, Corle D. Carcinoma of the extrahepatic bile ducts. Histologic types, stage of disease, grade, and survival rates. Cancer 1992;70:1498-1501.
5. Farley DR, Weaver AL, Nagorney DM. "Natural history" of unresected cholangiocarcinoma: patient outcome after noncurative intervention. Mayo Clin Proc 1995;70:425-429.
6. Takada T, Kato H, Matsushiro T, Nimura Y, Nagakawa T, Nakayama T. Comparison of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas. Oncology 1994;51:396-400.
7. Taal BG, Audisio RA, Bleiberg H, Blijham GH, Neijt JP, Veenhof CH, et al. Phase II trial of mitomycin C (MMC) in advanced gallbladder and biliary tree carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group Study. Ann Oncol 1993;4:607-609.
8. Falkson G, MacIntyre JM, Moertel CG. Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer 1984;54:965-969.
9. Okada S, Ishii H, Nose H, Yoshimori M, Okusaka T, Aoki K, et al. A phase II study of cisplatin in patients with biliary tract carcinoma. Oncology 1994;51:515-517.
10. Jones DV, Jr., Lozano R, Hoque A, Markowitz A, Patt YZ. Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas. J Clin Oncol 1996;14:2306-2310.
11. Kajanti M, Pyrhonen S. Epirubicin-sequential methotrexate-5-fluorouracil-leucovorin treatment in advanced cancer of the extrahepatic biliary system. A phase II study. Am J Clin Oncol 1994;17:223-226.
12. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10.
13. Duffy DE, Santner TJ. Confidence intervals for a binomial parameter based on multistage tests. Biometrics 1987;43:81-93.
14. Kaplan E, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-481.
15. Cox DR. Regression models and life tables. J R Stat Soc (B) 1972;74:187-220.
16. SAS/STAT user's guide. Version 7, Cary (NC). SAS Institute, Inc. 1989.
17. De Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med 1999;341:1368-1378.
18. Sanz-Altamira PM, O'Reilly E, Stuart KE, Raeburn L, Steger C, Kemeny NE, et al. A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma. Ann Oncol 2001;12:501-504.